Separately, sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated benefits in CKD patients with and without diabetes, particularly in delaying disease progression and reducing mortality risk. The gene discussed is SLC5A2; the disease is diabetes mellitus.